VIP

VIP (also known as Vasoactive Intestinal Peptide, Vasoactive Intestinal Polypeptide) is a prominently researched experimental compound classified strictly within the Neuropeptide framework. Operating primarily through advanced pharmacological pathways, its core mechanism of action is as follows: it 28-amino acid neuropeptide that binds VPAC1 and VPAC2 receptors, activating cAMP pathways to produce broad anti-inflammatory effects. Inhibits TNF-alpha, IL-6, and IL-12 production while promoting Th2/Treg tolerance. Potent pulmonary vasodilator and bronchodilator. Used in the Shoemaker CIRS protocol for Chronic Inflammatory Response Syndrome (biotoxin illness) to correct TGF-beta 1 dysregulation and restore immune homeostasis. with a documented biological half-life of roughly 0.033 hours, In preclinical investigative trials and independent academic studies, researchers utilizing VIP have documented significant, quantifiable biological outcomes, primarily focusing on systemic anti-inflammation, cirs/mold illness treatment, pulmonary vasodilation, immune modulation. Typical research protocols investigate administering 50 to 50mcg via nasal pathways 4x daily. However, it is critically important to understand that while VIP demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.